{"id":158487,"date":"2023-02-19T08:23:39","date_gmt":"2023-02-19T14:23:39","guid":{"rendered":"https:\/\/lifeboat.com\/blog\/2023\/02\/biontech-sees-uk-trials-on-cancer-vaccines-starting-this-year-paper-says"},"modified":"2023-02-19T08:23:39","modified_gmt":"2023-02-19T14:23:39","slug":"biontech-sees-uk-trials-on-cancer-vaccines-starting-this-year-paper-says","status":"publish","type":"post","link":"https:\/\/lifeboat.com\/blog\/2023\/02\/biontech-sees-uk-trials-on-cancer-vaccines-starting-this-year-paper-says","title":{"rendered":"BioNTech sees UK trials on cancer vaccines starting this year, paper says"},"content":{"rendered":"<p><a class=\"aligncenter blog-photo\" href=\"https:\/\/lifeboat.com\/blog.images\/biontech-sees-uk-trials-on-cancer-vaccines-starting-this-year-paper-says2.jpg\"><\/a><\/p>\n<p>BERLIN, Feb 19 (Reuters) \u2014 Clinical trials for BioNTech\u2019s <a data-testid=\"Link\" href=\"https:\/\/www.reuters.com\/companies\/22UAy.DE\" target=\"_blank\" class=\"\">(22UAy. DE)<\/a> cancer vaccines should start this year in Britain, marking an important step towards their possible sale on the open market, the German company\u2019s top executive Ugur Sahin told magazine Der Spiegel.<\/p>\n<p>BioNTech, known for its COVID vaccine with U.S. partner Pfizer <a data-testid=\"Link\" href=\"https:\/\/www.reuters.com\/companies\/PFE.N\" target=\"_blank\" class=\"\">(PFE.N)<\/a>, is currently deciding which types of cancer it wants to test its personalized cancer immunotherapies on and the locations where it will conduct the trials, Sahin said.<\/p>\n<p>The company wants these therapies, which are based on messenger RNA (mRNA) technology similar to the one that underpins its COVID-19 vaccine, to soon become a regular treatment for cancer patients.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>BERLIN, Feb 19 (Reuters) \u2014 Clinical trials for BioNTech\u2019s (22UAy. DE) cancer vaccines should start this year in Britain, marking an important step towards their possible sale on the open market, the German company\u2019s top executive Ugur Sahin told magazine Der Spiegel. BioNTech, known for its COVID vaccine with U.S. partner Pfizer (PFE.N), is currently [\u2026]<\/p>\n","protected":false},"author":396,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[11],"tags":[],"class_list":["post-158487","post","type-post","status-publish","format-standard","hentry","category-biotech-medical"],"_links":{"self":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/158487","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/users\/396"}],"replies":[{"embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/comments?post=158487"}],"version-history":[{"count":0,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/posts\/158487\/revisions"}],"wp:attachment":[{"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/media?parent=158487"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/categories?post=158487"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lifeboat.com\/blog\/wp-json\/wp\/v2\/tags?post=158487"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}